Abstract: The present invention relates to sulfamoyl benzoic acid derivatives of formula (I) or a pharmaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders which are mediated via the TRPM8 receptor.

Abstract: Disclosed is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a selective antagonist of a 5-HT2B receptor. The compound and salt are useful for treatment or prevention of various diseases and conditions associated with a 5-HT2B receptor.

Abstract: A multibranched polymer represented by the following formula (I), and a method for producing the multibranched polymer: where A represents an organic group having 3 or more branched chains, Xa represents a linking group containing any atom of Groups 14 to 16 in the Periodic Table, Y represents a functional group having a structure capable of having an active halogen atom, Q represents an arm moiety having a repeating unit derived from a polymerizable unsaturated bond, m1 represents any integer of 1 to the number of branched chains of A, m2 represents the number of branched chains of A, n1 represents an integer of 0 or 1 or more, and Ra represents an organic group that is not associated with the polymerization reaction.

Abstract: This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents ?1; A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; R1 represents an isopropyl group, a n-propyl group or a cyclopentyl group; R2 represents a methyl group, a fluorine atom or a chlorine atom; R3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1,

Abstract: The present invention provides a multibranched polymer represented by the following formula (I), and a method for producing the multibranched polymer: wherein A represents an organic group having 3 or more branched chains, Xa represents a linking group containing any atom of Groups 14 to 16 in the Periodic Table, Y represents a functional group having a structure capable of having an active halogen atom, Q represents an arm moiety having a repeating unit derived from a polymerizable unsaturated bond, m1 represents any integer of 1 to the number of branched chains of A, m2 represents the number of branched chains of A, n1 represents an integer of 0 or 1 or more, and Ra represents an organic group which is not associated with the polymerization reaction.

Abstract: This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: R1, R2, R3, A and m are each as described herein and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome.

Abstract: This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

Abstract: This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

Abstract: A polymer including a block chain A which is formed from a random copolymer containing a repeating unit (I) represented by the formula (I) wherein R1 to R3 each independently represents hydrogen or C1-10 hydrocarbon and R1 and R3 may bond to form a ring; R4a and R4b each independently represents hydrogen or methyl; R5 represents hydrogen, hydrocarbon, acyl, or silyl; and m represents any integer of 1 to 100 and when m is 2 or more and each R4a may be the same or different from one another and each R4b may be the same or different from one another; and a repeating unit (II) represented by the formula (II) wherein R6 and R8 each independently represents hydrogen or C1-10 hydrocarbon and R6 and R8 may bond to form a ring; R7 represents hydrogen, C1-10 hydrocarbon, hydroxyl, hydrocarbonoxy, carboxyl, acid anhydride, amino, ester, or an organic group having at least one functional group selected from the group consisting of hydroxyl, carboxyl, epoxy, acid anhydride, and amino; and R9 represents an

Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R1, R2, R3, R4 and R5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.

Abstract: This invention provides a compound of formula (I): wherein R1 represents an alkyl group having from 1 to 4 carbon atoms or a halogen atom, R2 represents an alkyl group having from 1 to 4 carbon atoms, R3 represents a hydrogen atom or a hydroxy group, and A represents an oxygen atom or a group of the formula —C(R4)(R5)— (in which R4 represents a hydrogen atom or an alkyl group having from 1 to 4 carbon atoms and R5 represents a hydroxy group or an alkoxy group having from 1 to 4 carbon atoms) or a pharmaceutically acceptable salts thereof. These compounds have 5-HT4 receptor agonistic activity, and thus are useful for the treatment of gastroesophageal reflux disease, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome or the like in mammalian, especially humans.

Abstract: This invention relates to compounds of the formula (I): or pharmaceutically acceptable salts thereof, wherein: R1, R2, R3, A and m are each as described herein and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageral disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes and apnea syndrome.

Abstract: This invention provides a compound of the formula (I): wherein Het represents a heterocyclic group having one nitrogen atom, to which B binds directly, and from 4 to 7 carbon atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 4 substituents independently selected from the group consisting of substituents ?1; A represents an alkylene group having from 1 to 4 carbon atoms; B represents a covalent bond or an alkylene group having from 1 to 5 carbon atoms; R1 represents an isopropyl group, a n-propyl group or a cyclopentyl group; R2 represents a methyl group, a fluorine atom or a chlorine atom; R3 independently represents (i) an oxo group, a hydroxy group, an amino group, an alkylamino group or a carboxyl group; (ii) a cycloalkyl group having from 3 to 8 carbon atoms, and said cycloalkyl group being substituted by 1 to 5 substituents, or (iii) a heterocyclic group having from 3 to 8 atoms, and said heterocyclic group being unsubstituted or substituted by 1 to 5 substituents, and n is 1,

Abstract: The present invention provides a multibranched polymer represented by the following formula (I), and a method for producing the multibranched polymer: wherein A represents an organic group having 3 or more branched chains, Xa represents a linking group containing any atom of Groups 14 to 16 in the Periodic Table, Y represents a functional group having a structure capable of having an active halogen atom, Q represents an arm moiety having a repeating unit derived from a polymerizable unsaturated bond, m1 represents any integer of 1 to the number of branched chains of A, m2 represents the number of branched chains of A, n1 represents an integer of 0 or 1 or more, and Ra represents an organic group which is not associated with the polymerization reaction.

Abstract: A polymer including a block chain A which is formed from a random copolymer containing a repeating unit (I) represented by the formula (I) wherein R1 to R3 each independently represents hydrogen or C1-10 hydrocarbon and R1 and R3 may bond to form a ring; R4a and R4b each independently represents hydrogen or methyl; R5 represents hydrogen, hydrocarbon, acyl, or silyl; and m represents any integer of 1 to 100 and when m is 2 or more and each R4a may be the same or different from one another and each R4b may be the same or different from one another; and a repeating unit (II) represented by the formula (II) wherein R6 and R8 each independently represents hydrogen or C1-10 hydrocarbon and R6 and R8 may bond to form a ring; R7 represents hydrogen, C1-10 hydrocarbon, hydroxyl, hydrocarbonoxy, carboxyl, acid anhydride, amino, ester, or an organic group having at least one functional group selected from the group consisting of hydroxyl, carboxyl, epoxy, acid anhydride, and amino; and R9 represents an

Abstract: An automatic player piano is broken down into an acoustic piano and an automatic playing system, and solenoid-operated key actuators are driven to rotate the black/white keys of the acoustic piano; the space between the keyboard and the array of black/white keys is so narrow that the manufacturer provides the solenoid-operated key actuators in the space below the key bed; plunger holes are formed in the rear portion of the key bed, and the solenoids occupy the space under the key bed so that the plungers project through the plunger holes into the space beneath the rear portions of the keys; the key bed is does not lose the mechanical strength so that the tuning work is not frequently required for the key action units.

Abstract: This invention relates to compounds of the formula (I): or a pharmaceutically acceptable salt thereof, wherein: A, R1, R2, R3, R4 and R5 are each as described herein or a pharmaceutically acceptable salt, and compositions containing such compounds and the use of such compounds in the treatment of a condition mediated by 5-HT4 agonistic activity such as, but not limited to, as gastroesophageal reflux disease, gastrointestinal disease, gastric motility disorder, non-ulcer dyspepsia, functional dyspepsia, irritable bowel syndrome (IBS), constipation, dyspepsia, esophagitis, gastroesophageal disease, nausea, central nervous system disease, Alzheimer's disease, cognitive disorder, emesis, migraine, neurological disease, pain, cardiovascular disorders, cardiac failure, heart arrhythmia, diabetes or apnea syndrome.

Abstract: This invention provides compounds of the formula (I) and (II): or the pharmaceutically acceptable esters thereof, and the pharmaceutically acceptable salts thereof: wherein R1 is hydrogen or halo; R2 and R3 are independently hydrogen or C1-6 alkyl; R4 and R5 are independently hydrogen or C1-6 alkyl; R6 is hydrogen, C1-12 alkyl, C1-6 alkoxy (C1-6)alkyl or C1-12 alkyl substituted by up to 3 substituents selected from the groups consisting of C3-8 cycloalkyl, aryl, heteroaryl and heterocyclic; R7 and R8 are hydrogen or taken together may form alkylene chain having one or two carbon atoms; R9 is C1-6 alkyl or C3-8 cycloalkyl; R10 is C1-6 alkyl or NR11R12; L is (CR11R12)n or NR11; M is NR11 or (CR11R12)n; R11 and R12 are independently hydrogen or C1-6 alkyl; n is an integer from 0 to 5; and m is an integer from 0 to 2; said heterocyclic, aryl and heteroaryl are unsubstituted or are substituted by at least one substituent selected from the group consisting of halo and C1-6 alkyl; with the proviso that when R9 i

Abstract: This invention relates to a compound of the formula: or a pharmaceutically acceptable salt thereof, wherein A and R1 are each an optionally substituted 5 to 6-membered heteroaryl, wherein the heteroaryl is optionally fused to a carbocyclic ring or 5 to 6-heteroaryl; R2 is NH2; R3 and R4 are each hydrogen, halo, (C1-C4)alkyl optionally substituted with halo and the like; and X1 to X4 are each hydrogen, halo, hydroxy, (C1-C4)alkyl optionally substituted with halo and the like. These compounds have COX-2 inhibiting activity and thus useful for treating or preventing inflammation or other COX-2 related diseases.

Abstract: An automatic player piano is broken down into an acoustic piano and an automatic playing system, and solenoid-operated key actuators are driven to rotate the black/white keys of the acoustic piano; the space between the keyboard and the array of black/white keys is so narrow that the manufacturer provides the solenoid-operated key actuators in the space below the key bed; plunger holes are formed in the rear portion of the key bed, and the solenoids occupy the space under the key bed so that the plungers project through the plunger holes into the space beneath the rear portions of the keys; the key bed is does not lose the mechanical strength so that the tuning work is not frequently required for the key action units.